UnitedHealth Group | A Healthcare Giant
Navigating Complexity while Presenting a Unique Investment Opportunity
DISCLAIMER & DISCLOSURE: The author holds a position in UnitedHealth Group at the date of publication but that may change. The views expressed are those of the author and may change without notice. The author has no duty or obligation to update this information. Some content is sourced from third parties believed to be reliable, but accuracy is not guaranteed. Forward-looking statements involve assumptions, risks, and uncertainties, meaning actual outcomes may differ from those envisaged in this analysis. Past performance is not indicative of future results. All investments carry risk, including financial loss. This analysis is for educational purposes only and does not constitute investment advice or recommendations of any kind. Conduct your own research and seek professional advice before investing.
UnitedHealth Group (NYSE: UNH) is one of the most complex and influential companies in the American healthcare system. At its peak, the company commanded a market capitalization exceeding $500 billion, placing it among the largest publicly traded businesses in the United States. Yet as of mid-2025, its valuation has fallen by close to 50% warranting a closer look. Is it now too cheap to ignore?
The drop reflects a confluence of challenges, operational missteps, leadership changes, external shocks, and heightened regulatory scrutiny. The result is uncertainty which has shaken investor confidence.
This is the kind of opportunity that investor Mohnish Pabrai looks for. He has explained how Wall Street commonly confuses risk and uncertainty - they are not the same thing. UnitedHealth Group is a far lower risk now that it has lost so much of its value because that risk is now baked in to the price. However, uncertainty remains - at least for the time being - and this could be an opportunity to profit handsomely from that confusion. Behind the stock's dramatic fall lies a business with robust fundamentals, unmatched scale, and a proven history of adaptability. Pabrai terms these opportunities as “Heads, I win; tails, I don't lose much” - in other words, they have a favourable asymmetric risk/reward skew.
Here, I’ll explore the case for investing in UnitedHealth Group and its future prospects within an increasingly politicized and complex healthcare ecosystem.
The Core of UnitedHealth Group
UnitedHealth Group is best understood as a two-engine model:
UnitedHealthcare, the health insurance division
Optum, the healthcare services arm.
Together, these four segments form a synergistic flywheel: UnitedHealthcare underwrites risk, while Optum provides the data, services, and care delivery infrastructure to manage that risk.
This vertical integration gives the business a distinct competitive advantage over standalone health insurers. It enables UnitedHealth to control pricing, clinical pathways, data and cost structures with precision.
That control, paired with its short-tail insurance business model, allows for annual repricing to adjust to prevailing market trends and healthcare costs. This is critical to this investment thesis because UnitedHealth recently missed an earnings target for the first time in 17 year, an issue that can be fixed through adjustments to pricing (more on this later).
The scale is staggering: over 150 million people are touched by the company’s operations, including 50 million medical insurance members and 70,000 employed or affiliated physicians.
To gain a better grasp of what this business is, it becomes necessary to explore its recent history.
The Back Story
In the early 1970s, Paul Ellwood, who later became known as the "Father of the Health Maintenance Organization” (HMO), founded the Minnesota-based health care think tank, Interstudy.
His HMO model was revolutionary in that it combined financing and care delivery by having health care providers treat a patient population for a prepaid cost. It focused on prevention and coordinated care using a primary care physician (PCP).
Ellwood succeeded in getting congressional approval for his HMO model and in 1971 he hired Richard Burke to help put the HMO model in to practice.
Initially, Burke established nonprofit HMOs in compliance with state laws, but in 1974, he founded Charter Medical, which would eventually evolve into the UnitedHealth Group we know today.
This model profoundly influenced UnitedHealth's evolution by establishing the foundational concept of integrated care management - the idea that an organization could both insure patients and directly manage their care to control costs and improve outcomes. UnitedHealth essentially took the HMO concept and scaled it massively through vertical integration.
Where traditional HMOs focused on coordinating existing providers, UnitedHealth built Optum to actually own and operate the care delivery infrastructure - employing physicians directly, running pharmacies, and using data analytics to manage the entire care cycle.
UnitedHealth Group became a publicly traded company in 1984, allowing for significant expansion and acquisitions throughout the 1990s and 2000s - notably purchasing MetraHealth in 1995, PacifiCare Health Systems in 2005.
The company underwent several reorganizations and rebranded as UnitedHealth Group in 1998 to reflect its broader range of health benefits and services.
Today, UnitedHealth Group is the largest healthcare company in the United States by revenue. Its sheer scale, which includes its vertically integrated model and all of the data that it owns, provides it with a competitive advantage and a formidable moat - disruption looks highly unlikely.
Hemsley as CEO: Visionary Expansion (2006–2017)
Stephen Hemsley's leadership from 2006 to 2017 was transformative. He oversaw the aggressive build-out of Optum and turned UnitedHealth into a truly diversified healthcare conglomerate.
Hemsley's background in finance brought a disciplined focus on profitability, cost control, and operational efficiency. During his tenure, revenue nearly tripled, and the stock significantly outperformed the S&P 500.
His acquisition strategy was focused but disciplined - domestically oriented and integrated within the core business.
He navigated the rollout of the Affordable Care Act with pragmatism, adjusting the company's offerings and operations to align with changing regulations.
By 2017, the year in which Hemsley stood down as CEO after 11 grueling years, UnitedHealth stood as a model of execution and consistency. Of note is that Hemsley did not exit the business, he transitioned to the less taxing task of becoming the Chairman.
Post-Hemsley Era: The Perfect Storm (2017-2025)
After Hemsley stepped down as CEO, a period of instability followed.
David Wichmann (2017–2021) and Andrew Witty (2021–2025) each brought new strategic priorities, but neither matched Hemsley's cohesive vision.
Wichmann was handed the baton in relation to international expansion. Hemsley had initiated the acquisition of the Brazilian company Amil Participações in 2013. It operated a network of hospitals, clinics, and had 5 million members. This was UnitedHealth’s first large-scale international bet.
Wichmann continued that drive, acquiring Banmédica in 2018. This marked UnitedHealth’s entry into Chile, Peru, and Colombia, reflecting an ambition to globalize the integrated healthcare model.
But these ventures ran into entrenched regulatory and economic hurdles. Amil, in particular, became a persistent loss generator due to tight pricing regulations and political interference. The Brazilian government's resistance to UnitedHealth's divestment attempts further exacerbated losses.
Then came COVID-19 which posed significant challenges to UnitedHealth, affecting nearly every aspect of its operations. While the lock-down resulted in delayed health care as all resource focused on the pandemic, short-term margins were boosted. However, this resulted in higher than expected utilization in the years that followed. The Medicare population, which is older and more vulnerable to COVID, experienced higher hospitalization and chronic condition burdens post-COVID. These utilization spikes distorted historical risk models, making pricing more difficult and leading to uneven margin performance. At the same time Optum Health faced higher staffing costs, burnout, and capacity constraints due to COVID surges. Physician shortages worsened, and wages rose across healthcare services, compressing margins. Home care and telehealth demand surged, forcing rapid digital adaptation and shifting care models - both an opportunity (more on this later) and a logistical strain. Ultimately, the shift required capital investment and recalibration of care delivery economics, particularly under value-based contracts.
Then there was the political turmoil. In the early stages of the pandemic UnitedHealth and other insurers posted record profits, due to reduced claims, while many Americans struggled to access care. This led to public and political scrutiny, with some accusing insurers of profiting from the crisis. UnitedHealth responded by rebating premiums and expanding COVID-related services such as at-home testing and vaccination support. This was largely done to offset criticism, but it came at a huge cost - particularly as claims surged post Covid.
While the company ultimately proved resilient, Wichmann didn’t even last 4 full years in charge of the business.
He was replaced by Andrew Witty who, despite his background in global healthcare and initial success, oversaw one of the most difficult periods in UnitedHealth's history.
He decided to reverse course on the company’s international ambitions. He sold Amil Participações in 2023, exiting Brazil. He, subsequently exited Peru in early 2025, and is in the process of divesting Banmédica in Chile and Columbia.
This misadventure had distracted management and diluted capital away from more profitable domestic opportunities, especially Medicare Advantage and Optum's expansion. (‘Medicare Advantage’ is defined in the next section).
The pandemic had accelerated telemedicine adoption, so Witty responded by integrating telehealth across Optum and employer offerings, often leveraging its AI/data infrastructure. But moving too fast can introduce vulnerabilities into the business. In 2024, UnitedHealth’s subsidiary, Change Healthcare, suffered a massive ransomware attack, paralyzing claims infrastructure and impacting 190 million Americans.
Operational chaos ensued, and the company faced reputational and legal fallout. Witty confirmed, during his appearance before the Senate Finance Committee, that the company paid a whopping $22 million in ransom to the hackers, but the true cost - the disruption to the business - was significantly higher, recorded at $1.95 billion.
To make matters worse, the senior management team sold tens of millions of dollars worth of shares on the day of the ransomware attack - which some have alleged amounted to insider trading. This hit shareholder confidence and was the catalyst that triggered the start of the slide in the share price. It was probably the beginning of the end for Andrew Witty.
Then in December 2024 came the cold blooded murder of Brian Thompson - CEO of subsidiary UnitedHealthcare - by Luigi Mangione, who authorities say was motivated by anger toward the U.S. health insurance industry. Witty was understandably shaken as he and other executives feared for their safety. Perhaps at this point he would have been happy to leave.
Finally, early in 2025, UnitedHealth recorded its first earnings miss since the 2008 financial crisis and pulled its 2025 guidance. This was driven largely by higher-than-expected medical costs in its Medicare Advantage book, revealing vulnerabilities in its cost forecasting models. The miss wasn’t huge, but both revenue and earnings came in below analyst expectations, with revenue of $109.6 billion (below the anticipated $111.6 billion) and adjusted earnings per share of $7.20–$7.27, also slightly below expectations. This did nothing to restore investor confidence and caused the share price to sell off further. This was the straw that broke the camels back and marked the end of the Witty era - his resignation took effect on May 12, 2025.
As if things weren’t already difficult, the Wall Street Journal revealed that the Department of Justice has opened an investigation into UnitedHealth’s Medicare Advantage billing. The company says it hasn’t been formally notified and stands by the integrity of its Medicare Advantage program.
That wasn’t the only regulatory headache. UnitedHealth is also facing an antitrust challenge over its $3.3 billion acquisition of Amedisys, a home health provider. The deal, made through its Optum unit, which already owns LHC Group, has raised concerns among regulators. They argue it could reduce competition and put pressure on patients and smaller providers. In response, UnitedHealth offered to sell parts of the business to Pennant Group and BrightSpring Health Services, but the DOJ rejected the latest proposal. The matter is now headed for mediation on August 18.
More broadly, UnitedHealth disclosed in its latest annual report that it’s under the microscope in multiple ways. The company is facing a wide range of investigations, audits, and reviews from agencies including the DOJ, IRS, Department of Labor, and the SEC.
It really has been a tempestuous time - a perfect storm - and that marked the end of Witty’s tenure as CEO.
Hemsley Returns: Back To Fundamentals
In the wake of these crises, 72 year old Hemsley returned as CEO in 2025 (Witty will remain as a senior adviser to support the transition).
Whether he decided to return voluntarily or was enticed by the board is not clear, but his remuneration package is really eye-watering. He’ll receive a base salary of $1 million per year, and although he will not receive any other cash or equity incentive compensation for the next three years, he has been awarded a one-time $60 million equity award in the form of nonqualified stock options, with the award vesting after three years (cliff vesting). The compensation structure is designed to incentivize Hemsley to remain as CEO for at least the three-year term and to align his interests with those of shareholders, as the options only have value if shareholder value is created.
Notwithstanding the $60 million options, a significant portion of Mr. Hemsley’s net worth is already invested in UnitedHealth Group, currently valued at over $400 million. After taking the CEO role, he purchased an additional $25 million shares (at an average price of $288.57 per share) further signaling his commitment to and stake in building long-term shareholder value. Chief Financial Officer John Rex followed suit, buying $5 million worth of shares at $291.12 per share. Additionally, board directors Tim Flynn, Kristen Gil, and John Noseworthy collectively acquired $1.6 million in stock.
This kind of insider buying in size is a green flag for external investors.
Did Hemsley need the $60m carrot at age 72 when he is already very wealthy and so heavily invested in the business? Probably not. But with no cash or equity incentives for three years, one thing is certain - he’ll not be distracted by short-term targets, instead he’ll be focused on what’s best for this business and its shareholders over the long-term. He has real skin in the game and his fortunes will move in lockstep with those of the company’s shareholders - true alignment.
His reappointment was seen as a move to restore financial discipline, operational focus and investor confidence. Hemsley himself acknowledged the company had lost its way, noting that "most of the challenges are within our control."
Early moves under his leadership include re-centralizing decision-making, revisiting Optum's acquisition pipeline with stricter criteria, and accelerating the divestiture of underperforming international assets. The board's choice reflects a belief that a return to fundamentals, and a focus on the U.S. healthcare opportunity, offers the best path forward.
This is a defining moment for the company. In today’s dislocated market, its undervalued stock offers investors a compelling entry point, just as one of the most strategically positioned players in U.S. healthcare begins to reignite its momentum.
So now I’ll break down the business model, its core strategic strengths, its economics and its valuation.
The Business Broken Down
Segment 1: UnitedHealthcare: The Insurance Division
The U.S. healthcare system is divided into three major insurance segments: private insurance, Medicare, and Medicaid, each serving a distinct demographic and functioning under different funding and administrative models.
Private insurance primarily covers working-age adults who receive coverage through their employers or purchase plans individually. This segment is funded by premiums from employers and employees and is largely administered by private insurers. UnitedHealth is a major player here, offering both fully insured group plans and administrative services for large employers who self-fund their insurance. While this market has historically been a profit center, it tends to grow more slowly than public programs and is susceptible to economic cycles.
Medicare, on the other hand, serves Americans aged 65 and older as well as certain disabled individuals. It comes in two primary forms: the traditional government-run program and the fast-growing Medicare Advantage (Part C), where private insurers like UnitedHealth deliver care and assume full financial risk. UnitedHealth is the largest Medicare Advantage provider in the country, earning government payments on a per-member, per-month basis. It also offers related plans like Part D prescription coverage and Medigap. The aging population and an increasing preference for managed care have made Medicare Advantage one of UnitedHealth’s most strategically important and reliable growth drivers, albeit one currently under regulatory scrutiny and cost pressure. (More on Medicare Advantage below).
Medicaid covers low-income individuals and families and is jointly funded by state and federal governments. States often contract with private insurers to manage this population under what’s called Managed Medicaid. UnitedHealth is a major player here too, operating Medicaid plans in many large states such as Texas and California. The company’s role is to coordinate care and manage costs while meeting strict quality standards.
Importantly, UnitedHealth’s presence across all three segments - Private, Medicare, and Medicaid - offers not just diversification but strategic synergy. Its analytics, clinical care models, and AI-driven cost management systems flow across these populations, reinforcing its position as a uniquely integrated and resilient force in U.S. healthcare.
Segment 2: Optum: The Underrated Growth Engine
Optum today contributes nearly half of UnitedHealth’s revenue and the majority of its operating profit. In fact, it would rank as a Fortune 50 company on a standalone basis.
It is comprised of Optum Health, OptumRx, and Optum Insight - a platform that is a vertically integrated powerhouse.
Optum Health delivers primary, specialty, and home care. It is the largest employer of physicians in the U.S., enabling value-based care at scale.
OptumRx is a top-three Pharmacy Benefit Manager (PBM), providing formularies, rebates, and drug management services. PBMs generate revenue through administrative fees, a share of negotiated rebates from drug manufacturers, and sometimes by retaining a portion of the difference between what insurers pay and what pharmacies are reimbursed (known as “spread pricing”).
Optum Insight offers analytics, technology platforms, and billing services, with a $33 billion backlog and high-margin, recurring revenue.
What sets Optum apart is its ability to channel patients into UnitedHealth’s own clinical network, manage their care, and feed data back into underwriting models. This creates a continuous learning loop - a self-reinforcing flywheel that few competitors can match.
Over the past decade, Optum has been grown through disciplined bolt-on acquisitions rather than megamergers. This approach avoided regulatory roadblocks, made integration easier to manage and preserved strategic control.
UnitedHealth’s Advantages
AI and the Data Advantage
In an era of rapid technological progress, particularly with the rise of AI, the biggest winners are likely to be the companies that use these tools effectively, not necessarily those that build them. A great example is Domino’s Pizza, which delivered exceptional returns to shareholders not by inventing new tech, but by applying it strategically across its operations. As I discussed in a previous post, Domino’s outperformed even the tech sector by leveraging technology to streamline delivery, ordering, and logistics. The same pattern is emerging with AI: the real value may lie with the adopters, not just the innovators and this is particularly relevant in this investment thesis.
UnitedHealth has become a leader in applying AI and machine learning across its operations. With data from over 50 million covered lives and deep visibility into pharmacy, provider, and diagnostic data, UnitedHealth has one of the richest longitudinal healthcare datasets globally which is an asset that should not be undervalued - yet it doesn’t appear on the balance sheet.
This data is being used to:
Predict patient deterioration and offer earlier intervention
Improve adherence to care plans and medication regimens
Optimize provider performance through benchmarking and clinical guidelines
Streamline claims processing and reduce fraud
Critically, unlike peers who apply AI in isolated functions, UnitedHealth integrates these tools across the entire care and risk chain - from pricing insurance to scheduling home visits. This holistic integration provides real-time responsiveness and margin enhancement capabilities.
The company has also started using generative AI to draft documentation, improve call center efficiency, and streamline administrative functions, cutting down on overhead. As AI training scales, these capabilities are expected to enhance profitability further while improving patient satisfaction.
Value-Based Care and Capitation (the per capita model)
Traditional U.S. healthcare reimburses providers per procedure (fee-for-service), arguably creating the wrong incentives - revenues are optimized when people are sick and need treatment.
UnitedHealth is leading a shift to value-based care, particularly through capitation models that pay providers a fixed amount per patient. This change aligns incentives: the less a patient needs expensive care, the more margin the provider retains - so here revenues are optimized by keeping people healthy.
Optum Health's large physician network enables this shift, while AI-driven risk stratification supports early intervention.
In practice, this means fewer emergency visits, more telehealth check-ins, and better management of chronic diseases. Over time, value-based care reduces volatility and improves predictability - though it does expose the company to short-term spikes in utilization, as seen in 2024.
The company reported that over 4 million lives were under fully capitated arrangements in 2024, and it aims to grow this base by double digits annually. Value-based care is not only a margin lever but a political buffer as it aligns UnitedHealth with policymakers’ goals to reduce national healthcare spending. This is hugely beneficial in an industry that is constantly the subject of regulatory scrutiny and ongoing debate - particularly in respect of transparency and pricing.
Medicare Advantage
Medicare Advantage (MA) is UnitedHealth's most important growth vertical. Covering nearly one-third of its insured population, MA combines public funding with private management. However, MA has come under fire:
Regulators accuse insurers of aggressive coding to inflate risk scores
Rising utilization among new enrollees has driven up costs
Media scrutiny and political rhetoric have intensified, especially around claim denials
Centers for Medicare and Medicaid Services (CMS) created a star rating system to help Medicare-eligible individuals and caregivers quickly compare the performance and quality of Medicare Advantage plans and Part D prescription drug plans. This rating system helps Medicare shoppers and caregivers evaluate different plans – an important factor for someone enrolling for the first time or considering a change during the Medicare Annual Enrollment Period.
Here’s what the star ratings mean:
5-star rating: excellent performance
4-star rating: above-average performance
3-star rating: average performance
2-star rating: below-average performance
1-star rating: poor performance
CMS statistics for 2025 show that, across the industry, about 62% of MA-PD (Medicare Advantage with prescription drug coverage) enrollees are in plans rated 4 stars or above.
UnitedHealth continues to outperform peers and over 73% of its MA members are enrolled in 4-star or higher plans.
Net promoter scores (NPS) also suggest consumer satisfaction remains high relative to peers. The company has taken proactive steps to increase claim approvals and smooth member experience, likely a tactical decision to protect brand equity amid political scrutiny.
Overall, UnitedHealthcare’s large market share - 28.5% of Medicare Advantage members in 2025 - suggests strong consumer trust.
Regulatory Risk
Healthcare in the U.S. is inherently political. Drug pricing, pharmacy benefit managers (PBMs), and Medicare costs are constant flashpoints, debated in Congress, during presidential campaigns, and across the media. At the heart of these discussions are questions of affordability, access, and efficiency.
Under the Trump administration, policy unpredictability certainly increased, but sweeping structural reforms were limited. The Affordable Care Act (ACA) withstood multiple repeal attempts, though the administration did push through some changes - such as granting states more flexibility around Medicaid expansion and experimenting with alternative payment models.
It should be borne in mind that on May 11, 2018, during his first term, President Trump unveiled the “American Patients First” blueprint, aiming to reduce drug prices. The proposal included efforts to increase drug price transparency, reform rebate structures involving PBMs, and explore international reference pricing. Trump also floated the idea of eliminating PBMs as middlemen to lower prices by letting patients or plans buy directly from manufacturers, although this proposal was never fully implemented. Will he try again?
Meanwhile, Optum Rx - UnitedHealth’s PBM - is addressing concerns by proactively redesigning its reimbursement model, shifting away from traditional incentives that favoured generics or brand-name drugs. Instead, it plans to adopt a cost-based pricing model - reimbursing pharmacies based on the actual acquisition cost of a drug plus a fixed dispensing fee. This overhaul, driven by the rising use and cost of GLP-1s and other specialty drugs, is expected to be fully in place by 2028.
Whatever the future holds, if the past is a good gauge, UnitedHealth has proven adept at navigating reforms:
It adapted to the ACA with minimal disruption.
It withstood "Medicare for All" rhetorical challenges, avoiding fundamental business model shifts, as the initiative was unable to advance legislatively.
It continues to adjust to CMS and DOJ actions and has a track record of responding to regulatory and legal challenges - such as star rating disputes and antitrust scrutiny - with legal, operational and reputational strategies.
It is also worthy of note that while regulation may compress margins temporarily, it tends to consolidate share among incumbents. Smaller players lack the compliance infrastructure and capital flexibility to keep pace. Ironically, tighter rules often entrench UnitedHealth's dominance.
The likely regulatory risk scenario involves adjustments to MA risk scoring and PBM rebate transparency, all manageable headwinds for a company of UnitedHealth’s scale.
Competitive Landscape
To fully appreciate UnitedHealth’s position, it’s essential to compare it with major competitors such as CVS Health (Aetna), Cigna, Humana, and Elevance Health (formerly Anthem):
CVS Health, while formidable due to its acquisition of Aetna and its massive retail footprint, lacks the tight integration of clinical care and insurance that UnitedHealth provides. The CVS model relies more heavily on physical retail, which is under pressure, and its execution in digital transformation has lagged behind.
Cigna, with its focus on pharmacy benefits through Express Scripts and commercial insurance, does not compete meaningfully in Medicare Advantage at UnitedHealth’s scale. Its absence from clinical delivery also means it cannot generate the feedback loop between insurance, care delivery, and data that defines the UnitedHealth flywheel.
Humana, once considered a potential peer in Medicare Advantage, has become more niche and more vulnerable. Its exposure is concentrated in one high-risk, low-margin area, with limited service diversification. The recent downgrades in CMS star ratings also put Humana at a disadvantage.
Elevance Health was late to the integrated model, and its acquisition strategy focused on horizontal expansion. Only in recent years has Elevance begun to build service assets - but it’s a long way behind UnitedHealth.
The competitive landscape reinforces one core reality: UnitedHealth is a decade ahead in building a complete, vertically integrated healthcare ecosystem. Its size, data richness, and infrastructure are difficult to replicate, and any attempt by competitors to catch up will be slow and capital intensive.
Strategic Optionality and Future Growth Vectors
While Optum and Medicare Advantage remain the most visible pillars of growth, UnitedHealth has multiple optionality levers it can activate to extend its lead:
Expansion into Home Health: With the aging population and rising demand for convenience, UnitedHealth’s investment in home care could shift higher-acuity patients out of hospitals. This aligns with its value-based strategy and enables lower-cost, high-outcome interventions.
Behavioral Health and Mental Wellness: Rising demand for mental health services creates opportunities for margin expansion. Optum’s growing focus on integrating behavioural care into primary settings positions UnitedHealth as a front-runner in this next frontier of managed care.
Direct-to-Consumer Health Offerings: While most of UnitedHealth’s business is B2B (employer/government plans), the rise of digital health enables direct enrollment, virtual primary care, and wellness offerings direct to consumer. This could unlock a new, high-margin sales channel.
AI Commercialization and Licensing: UnitedHealth is already using proprietary AI for internal cost control and operational improvements. Over time, it may choose to license or white-label elements of its technology stack to third-party payers or providers.
Unlocking Value in Data: UnitedHealth has the most comprehensive set of data which would be invaluable for medical research purposes. Subject to not breaching legal confidentiality requirements, this could be a high margin resource when paired with .
These vectors, while secondary today, could drive incremental growth in the second half of the decade.
ESG and Societal Impact
UnitedHealth’s scale brings scrutiny, but also responsibility. In recent years, the company has expanded its ESG disclosures, focusing on equitable access to care, sustainable operations, and workforce diversity.
It has committed to:
Reducing healthcare disparities across race and income
Expanding virtual care in rural and underserved areas
Lowering emissions from healthcare delivery and facilities
Training and supporting a more diverse pipeline of healthcare professionals
Though ESG factors rarely drive short-term valuation, they are increasingly relevant for institutional investors seeking durable, socially responsible growth. UnitedHealth’s ability to deliver financial performance while enhancing its social license to operate positions it well in an era of stakeholder capitalism.
Financials and Valuation
As explained earlier, FY2024 was not the finest in the history of UnitedHealth, with margins being hit and coming in softer than in any of the preceding five years. Gross margins were down 220bp and operating margins down 60bp year on year. However, The following diagram demonstrates how money flowed through the business.
Gross margins (not shown) are consistently above 23%, recently closer to 24.5%, and operating margins average 8.5%. High volume businesses can thrive on relatively low margins - just ask Walmart - and tight margins also serve as a barrier to entry as new entrants don’t have the critical mass to make the economics work, so this is all good.
Revenues have grown steadily and sequentially at just over 10% CAGR over the past decade, so this is clearly a robust business with an entrenched oligopolistic position in a core industry.
Last year the international segment generated a mere $3.7 billion in revenue with EBITDA of approximately $222 million, accounting for ~1% of the company’s total sales and profits. So, it becomes clear why divesting the Latin American parts of the business makes perfect sense. It was a costly mistake, and the divestment will result in a capital loss, but the best course of action is to draw a line under that chapter and move on.
EBITDA now exceeds $40 billion annually and, from 2014 to 2024, free cash flow per share compounded at 13% - a rare feat for a business of this size.
Yet today, UnitedHealth trades at a forward P/E of less than 13x and under 10x forward EV/EBITDA, well below its long term average and at a significant discount to peers like Elevance Health (~13x) and Cigna (~11x), especially given UnitedHealth’s larger scale and more diversified earnings base.. The market seems to have discounted the stock as though the company’s margins are permanently impaired, despite the short-term nature of its insurance pricing cycle.
A simple sum-of-the-parts analysis suggests the market is undervaluing UnitedHealth considerably. If Optum were valued independently at 14x EBITDA (in line with other tech-enabled healthcare services), it could justify $200 billion of enterprise value alone. That implies the insurance business, still the dominant provider in employer and government-sponsored coverage, is being severely undervalued.
The dividend yield now exceeds 2.6% - nearly double its historical average, which is another sign of undervaluation - and the company continues to buy back shares opportunistically. With net debt/EBITDA under 1.4x and substantial free cash flow, balance sheet flexibility remains strong.
UnitedHealth’s business model is notoriously difficult to model. Its success relies on understanding an intricate web of insurance pricing, clinical care delivery, AI infrastructure, and regulatory navigation. This complexity often leads to underappreciation by generalist investors, particularly during times of volatility.
But therein lies the opportunity.
The current market sell-off, driven by headlines and short-term challenges, masks the durable value creation that underlies UnitedHealth’s flywheel. For investors willing to do the work, the dislocation provides a rare chance to acquire a best-in-class compounder at a discounted valuation.
Historically, such windows have been brief. Following regulatory scares in 2012, political fears in 2016, and pandemic confusion in 2020, UnitedHealth’s shares rebounded and delivered multi-year outperformance. The setup today bears strong resemblance to those prior moments of opportunity.
Is UnitedHealth Group (UNH) a good Investment?
There is no doubt that UnitedHealth is experiencing one of the most challenging periods in its modern history. Cyberattacks, the tragic loss of an executive, cost pressures, a regulatory overhang and a change in leadership have all converged. But the underlying engine, a fully integrated insurer-provider platform with unparalleled data, scale, and capital discipline, remains fully intact.
While I never usually invest in a company with a new CEO, because doing so is like rolling the dice of chance, Hemsley is not a new CEO. He served in that role for 11 years previously and then a further eight years as chairman. He has never been out of the business and, with two decades in the company, he understands it better than anyone.
With Hemsley back at the helm, it marks a turning point in refocusing the company on operational rigor, disciplined capital allocation and a U.S. centric strategy. With a renewed domestic focus, a fortress-like balance sheet, unwavering long-term demand for healthcare services, plus continued investment in AI and value-based care, UnitedHealth is positioned to prosper.
Extraordinary costs relating to the divestment of Latin American businesses and the unfortunate cybersecurity incident will be firmly in the rear-view mirror, with margin recovery and greater efficiency clearly on the road ahead.
This isn’t a contrarian bet on a broken model, but a rational bet on a temporary dislocation in a dominant player. With the flywheel intact, margins are set to rebound and optionality expanding, UnitedHealth Group stands ready to resume its path as one of the most powerful compounding stories in public markets. Few machines in American business turn as efficiently.
Investors today have the benefit of hindsight: the model has worked, the strategy is proven, and, with a growing and aging population, the opportunity remains massive. The U.S. healthcare system still suffers from fragmentation, inflation, and inefficiency. No company is better positioned to address that than UnitedHealth.
For long-term investors, today’s dislocation is an opportunity to own one of the most strategically advantaged companies in U.S. healthcare at a deep discount.
UnitedHealth will release its second quarter 2025 financial results on Tuesday, July 29, before the market opens, and will host a teleconference at 8:45 a.m. ET to discuss the results with analysts and investors.
Is now the time to own it?
You decide.
UnitedHealth Group, Q3 2025 results
The company beat lowered consensus expectations for its third quarter 2025 earnings and raised its full-year guidance, even though operating earnings fell sharply year over year.
The sharp drop in operating profit largely reflects persistently high medical costs, reduced Medicare funding, and competitive pressures in Medicaid and Medicare Advantage.
Despite these headwinds, the domestic insurance segment posted robust membership gains and Optum's pharmacy services contributed meaningfully.
Management acknowledges the Medicaid business will remain challenged through 2026, but expects a turnaround by 2027.
The company expressed optimism by raising its 2025 adjusted EPS outlook from $16.00 to at least $16.25 per share, and net earnings guidance from at least $14.50 to $14.90 per share.
Q3 operating cash flow reached $5.9 billion, supporting confidence in future growth.
CEO Stephen Hemsley emphasized a refocus on performance and "durable and accelerating growth" for 2026 and beyond.
We recently learned that Warren Buffet at Berkshire Hathaway has been investing in UnitedHealth, but other notable investors are also appearing on the share register.
UNH is now the second largest holding of David Tepper at Appaloosa Holdings (11.85% of his fund).
Even Michael Burry, made famous by the 'Big Short' movie which chronicled how he made billions by correctly calling the sub-prime crisis before it happened, has gained exposure to UNH through the options market via his Scion Asset Management vehicle.
Would you bet against these people?